Last reviewed · How we verify
Telavancin Injection
Telavancin Injection is a Small molecule drug developed by Aaron Cook. It is currently FDA-approved. Also known as: Vibativ.
Telavancin Injection is a protein-based medication. It is used to treat various conditions, including acute pulmonary exacerbations in cystic fibrosis adults, as per the study "Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations".
At a glance
| Generic name | Telavancin Injection |
|---|---|
| Also known as | Vibativ |
| Sponsor | Aaron Cook |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage (PHASE4)
- Telavancin Pharmacokinetics in Cystic Fibrosis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Telavancin Injection CI brief — competitive landscape report
- Telavancin Injection updates RSS · CI watch RSS
- Aaron Cook portfolio CI
Frequently asked questions about Telavancin Injection
What is Telavancin Injection?
Who makes Telavancin Injection?
Is Telavancin Injection also known as anything else?
What development phase is Telavancin Injection in?
Related
- Manufacturer: Aaron Cook — full pipeline
- Also known as: Vibativ
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing